within Pharmacolibrary.Drugs.ATC.B;

model B05AA02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.3333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05AA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Other plasma protein fractions are purified preparations containing a variety of plasma proteins excluding immunoglobulins. They are typically used as plasma expanders in the treatment or prevention of shock due to blood loss, burns, or hypoalbuminemia, especially when plasma or albumin is not available. Their use today is limited due to improved alternatives such as albumin solutions, crystalloids, and colloids. Not currently a first-line therapy and rarely used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for intravenous administration in adult humans, as specific published PK studies for this ATC-defined group are lacking.</p><h4>References</h4><ol><li><p>Tan, AR, et al., &amp; Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>The Lancet. Oncology</i> 22(1) 85–97. DOI:<a href=\"https://doi.org/10.1016/S1470-2045(20)30536-2\">10.1016/S1470-2045(20)30536-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33357420/\">https://pubmed.ncbi.nlm.nih.gov/33357420</a></p></li><li><p>Koo, TS, et al., &amp; Moon, H (2011). Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. <i>Archives of pharmacal research</i> 34(12) 2059–2064. DOI:<a href=\"https://doi.org/10.1007/s12272-011-1208-7\">10.1007/s12272-011-1208-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22210031/\">https://pubmed.ncbi.nlm.nih.gov/22210031</a></p></li><li><p>Hvidberg, EF, &amp; Dam, M (1976). Clinical pharmacokinetics of anticonvulsants. <i>Clinical pharmacokinetics</i> 1(3) 161–188. DOI:<a href=\"https://doi.org/10.2165/00003088-197601030-00001\">10.2165/00003088-197601030-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/797496/\">https://pubmed.ncbi.nlm.nih.gov/797496</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05AA02;
